文献速递类风湿关节炎

开发用于支持类风湿关节炎共享决策的交互式工具:治疗属性偏好

Development of an Interactive Tool to Support Shared Decision-Making in Rheumatoid Arthritis: Treatment Attribute Preference.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2023-11-13

该研究通过定性访谈(类风湿关节炎患者10例、风湿科医生10例)和定量调查(944例类风湿关节炎患者)两阶段,评估患者对治疗属性(给药途径与给药频率、严重副作用、自付费用、疗效、监测要求)的偏好。结果显示给药途径与给药频率(38%)和严重副作用(33%)是患者最重要的两个治疗属性;再测调查(172/944)估计工具稳定性为72%(124/172)。

要点

  • 定性访谈中患者10例和风湿科医生10例对共享决策工具设计的反馈用于构建定量调查。
  • 944例类风湿关节炎患者中,给药途径与给药频率(38%)和严重副作用(33%)是最重要的两个治疗属性。
  • 再测调查(172/944)估计工具在治疗属性相对重要性方面的稳定性为72%(124/172)。

核心结论

  • 该调查结果可用于开发共享决策工具,该工具可能有助于了解患者偏好,且患者和风湿科医生普遍接受度良好,具有良好的一致性和可靠性。

研究设计与样本

  • 两阶段调查:定性访谈(类风湿关节炎患者10例、风湿科医生10例)和定量调查(944例类风湿关节炎患者)。
  • 定量调查采用自适应联合分析,对假设的类风湿关节炎治疗方案配置进行排序,评估患者对治疗属性的偏好。

主要发现

  • 定量调查共944例类风湿关节炎患者参与(男性43%,女性57%)。
  • 给药途径与给药频率(38%)和严重副作用(33%)是个体患者最重要的两个治疗属性。
  • 再测调查(172/944)估计工具在治疗属性相对重要性方面的稳定性为72%(124/172)。

关键数值与推荐

  • 评估的治疗属性包括给药途径与给药频率、严重副作用、自付费用、疗效和监测要求。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: An interactive tool identifying treatment attributes important to patients can enhance shared decision-making (SDM) in rheumatoid arthritis (RA). A formative survey was conducted to identify the most important treatment attributes from patients' perspective, which can be used to develop an interactive SDM tool. METHODS: The survey was performed in two phases: qualitative interviews and quantitative surveys. The qualitative interviews were conducted to inform the design of the quantitative survey. In qualitative interviews, patients with RA (n = 10) and rheumatologists (n = 10) were introduced to the SDM tool concept. Feedback on the design and scope of the SDM tool was used to develop a quantitative survey, conducted in a large sample size of patients. Patient preferences for treatment attributes (route of administration and dosing frequency, serious side effects, out-of-pocket costs, efficacy, and monitoring requirement) were assessed via adaptive conjoint exercise involving ranking of hypothetical RA treatment configurations. RESULTS: A total of 944 patients (males: 43%, females: 57%) with RA participated in the quantitative survey. Route of administration and dosing frequency (38%) followed by serious side effects (33%) were the two most important treatment attributes for individual patients. The recontact survey (n = 172/944) estimated tool stability of 72% (n = 124/172) in terms of the relative importance of treatment attributes. CONCLUSION: The findings of this survey could be used in the development of an SDM tool that can potentially provide insights into patient preferences and is generally well received by patients and rheumatologists with good agreement and reliability.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Curtis JR, Ford K, Fiore S, et al. Development of an Interactive Tool to Support Shared Decision-Making in Rheumatoid Arthritis: Treatment Attribute Preference. Arthritis Care Res (Hoboken). 2023. PMID: 37652871. doi:10.1002/acr.25223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。